therapeutic platform offering sustained drug release and improved patient adherence across a range of indications—from mental health and contraception to infectious diseases and metabolic disorders. However, evaluating LAIs in early-phase trials introduces unique pharmacokinetic, safety, and ethical challenges. Phase 1 studies of LAIs must balance prolonged exposure risks, depot kinetics, and delayed adverse events, often requiring specialized designs and real-time monitoring. This tutorial explores the complexities of designing Phase 1 studies for long-acting injectable drugs and outlines strategies for mitigating dosing and safety risks.

What Are Long-Acting Injectables?

Long-acting injectables are formulations designed to release active pharmaceutical ingredients (APIs) over extended periods—ranging from weeks to several months—via parenteral administration. These formulations may include:

• Depot suspensions (e.g., microspheres, liposomes)
• Polymer-based in situ gels
• Intramuscular (IM), subcutaneous (SC), or intradermal routes
• Oil-based or crystalline suspensions

Why Are Phase 1 Trials for LAIs Challenging?

• Prolonged drug exposure: Single dose may last weeks or months
• Dose escalation is slow: Cannot rapidly adjust dose after administration
• Difficult PK modeling: Multi-phase absorption with flip-flop kinetics
• Safety management: Adverse events may have delayed onset and long duration
• Depot reversibility: Once injected, drug may not be removable

Regulatory Expectations for LAI Phase 1 Studies

FDA

• Requires detailed justification of depot selection and preclinical PK/TK modeling
• Strongly encourages sentinel dosing and staggered enrollment

EMA

• Recommends complete in vitro/in vivo release correlation prior to human exposure
• Mandates follow-up of at least 5 half-lives of the release phase

CDSCO

• Permits LAIs in Phase 1 with clear dose rationale and depot kinetics data

Study Design for LAI Evaluation

1. Single-Dose PK and Safety Studies

• Start with the lowest effective or predicted therapeutic dose
• Monitor over weeks or months depending on release kinetics

2. Crossover Design (Rare)

• Only feasible if washout is short (e.g., depot dissolves in 2–4 weeks)
• Otherwise, parallel design is preferred

3. Adaptive Escalation Design

• Use sentinel subjects for each cohort
• Require extended review period between doses (≥28 days typical)

4. Route Comparison Studies

• Compare SC vs IM for depot consistency and AE profile

Dosing and Depot-Related Considerations

Depot Design

• Predictive in vitro release profiles must match observed in vivo performance
• Site of injection (gluteal vs deltoid) can influence release rate

Injection Volume and Viscosity

• Volume often >1 mL; requires large-bore needles and may cause injection site pain
• Viscosity impacts delivery pressure and syringe compatibility

Repeat Dose Feasibility

• Not typically performed in Phase 1 unless prior oral PK exists
• Risk of drug accumulation or immune response upon repeat injection

Pharmacokinetic Assessments

Sampling Strategy

• Must cover entire absorption and elimination phase—up to 3 months in some cases
• Frequent sampling early (Day 1–7), followed by sparse sampling (Weeks 2–12)

Key PK Parameters

• Cmax, Tmax: May be delayed days or weeks after injection
• AUC_0–t, AUC_0–∞: Reflects long-term exposure
• Apparent t_½: Influenced by release rate rather than elimination rate (flip-flop kinetics)

Safety and Tolerability Monitoring

Local Tolerability

• Injection site pain, erythema, induration
• Use visual analog scale (VAS) and standardized questionnaires

Systemic Safety

• Monitor for delayed systemic toxicity (e.g., hepatotoxicity, immune reactions)
• Weekly labs for at least 4–8 weeks post-dose

Reversibility Planning

• Develop stopping criteria if systemic toxicity occurs
• Some agents may require antagonists or detoxification strategies

Bioanalytical and Depot Release Assessments

• Stability testing of depot formulation in simulated physiological fluids
• LC-MS/MS validation for slow-release PK profiles
• Exploratory imaging studies (e.g., MRI) to track depot dissolution

Case Examples

1. Injectable Antipsychotic (e.g., Paliperidone Palmitate)

• Depot detectable in blood up to 90 days post-dose
• Injection site pain and sedation as primary AEs

2. Long-Acting HIV Integrase Inhibitor

• Required 12-month follow-up due to low elimination rate
• Delayed hypersensitivity reaction reported after 3 weeks

Best Practices for Phase 1 LAI Trials

• Start with lowest feasible dose and slow escalation schedule
• Use real-time PK review before enrolling next cohort
• Ensure depot reversibility planning in high-risk trials
• Predefine stopping rules for both systemic and local AEs
• Use validated bioanalytical methods for long-duration sampling